Efficacy of Avelumab Plus Axitinib Versus Sunitinib by Numbers of IMDC Risk Factors and Target Tumor Sites at Baseline in Advanced Renal Cell Carcinoma: Long-term Follow-up Results from JAVELIN Renal 101

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2023 Oct 22

PMID 37866029

Authors

Y Tomita

R J Motzer

T K Choueiri

B I Rini

H Miyake

M Oya

L Albiges

M Aizawa

Y Umeyama

J Wang

A di Pietro

M Schmidinger

Affiliations

Soon will be listed here.

Abstract

Background: In the phase III JAVELIN Renal 101 trial, first-line avelumab + axitinib improved progression-free survival (PFS) and objective response rate versus sunitinib in patients with advanced renal cell carcinoma across all International Metastatic RCC Database Consortium (IMDC) risk groups (favorable, intermediate, and poor); analyses of overall survival (OS) remain immature. Here, we report post hoc analyses of efficacy from the third interim analysis (data cut-off, April 2020) by the numbers of IMDC risk factors and target tumor sites at baseline.

Methods: Efficacy endpoints assessed were PFS, objective response, and best overall response per investigator assessment (RECIST v1.1) and OS. Best percentage change and percentage change from baseline in target tumor size over time during the study were also assessed.

Results: In patients with 0, 1, 2, 3, or 4-6 IMDC risk factors, hazard ratios [HRs; 95% confidence interval (CIs)] for OS with avelumab + axitinib versus sunitinib were 0.660 (0.356-1.223), 0.745 (0.524-1.059), 0.973 (0.668-1.417), 0.718 (0.414-1.248), and 0.443 (0.237-0.829), and HRs (95% CIs) for PFS were 0.706 (0.490-1.016), 0.709 (0.540-0.933), 0.711 (0.527-0.960), 0.501 (0.293-0.854), and 0.395 (0.214-0.727), respectively. In patients with 1, 2, 3, or ≥4 target tumor sites, HRs (95% CIs) for OS with avelumab + axitinib versus sunitinib were 0.912 (0.640-1.299), 0.715 (0.507-1.006), 0.679 (0.442-1.044), and 0.747 (0.346-1.615), and HRs (95% CIs) for PFS were 0.706 (0.548-0.911), 0.552 (0.422-0.723), 0.856 (0.589-1.244), and 0.662 (0.329-1.332), respectively. Across all subgroups, analyses of objective response rate and complete response rate favored avelumab + axitinib versus sunitinib, and a greater proportion of patients treated with avelumab + axitinib had tumor shrinkage.

Conclusions: In post hoc analyses, first-line treatment with avelumab + axitinib was generally associated with efficacy benefits versus treatment with sunitinib in patients with advanced renal cell carcinoma across subgroups defined by different numbers of IMDC risk factors or target tumor sites.

Citing Articles

Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.

Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N Int J Clin Oncol. 2025; .

PMID: 39934514 DOI: 10.1007/s10147-024-02655-4.

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study.

Tsimafeyeu I, Chubenko V, Baklanova O, Kalpinskiy A, Safina S, Lebedinets A Curr Oncol. 2025; 32(1).

PMID: 39851927 PMC: 11764420. DOI: 10.3390/curroncol32010011.

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.

Tasaki Y, Hamamoto S, Yamashita S, Furukawa J, Fujita K, Tomida R Front Immunol. 2025; 15():1483956.

PMID: 39850887 PMC: 11754295. DOI: 10.3389/fimmu.2024.1483956.

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.

Zhou Y, Liu Z, Yu A, Zhao G, Chen B Immunotargets Ther. 2025; 13:813-829.

PMID: 39763508 PMC: 11700879. DOI: 10.2147/ITT.S494670.

Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma.

Shah N, Shinde R, Moore K, Sainski-Nguyen A, Le L, Cao F JAMA Netw Open. 2024; 7(7):e2422674.

PMID: 39052293 PMC: 11273232. DOI: 10.1001/jamanetworkopen.2024.22674.

References

Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M . Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open. 2022; 7(5):100564. PMC: 9588905. DOI: 10.1016/j.esmoop.2022.100564. View

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

Haanen J, Larkin J, Choueiri T, Albiges L, Rini B, Atkins M . Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023; 8(3):101210. PMC: 10265611. DOI: 10.1016/j.esmoop.2023.101210. View

Motzer R, Powles T, Burotto M, Escudier B, Bourlon M, Shah A . Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(7):888-898. PMC: 10305087. DOI: 10.1016/S1470-2045(22)00290-X. View

Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T . Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol. 2016; 46(11):1031-1041. PMC: 5091032. DOI: 10.1093/jjco/hyw103. View

Escudier B, Motzer R, Tannir N, Porta C, Tomita Y, Maurer M . Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol. 2019; 77(4):449-453. PMC: 7521478. DOI: 10.1016/j.eururo.2019.10.025. View

Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021; 384(9):829-841. PMC: 8436591. DOI: 10.1056/NEJMoa2026982. View

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

10.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

11.

Vaishampayan U, Schoffski P, Ravaud A, Borel C, Peguero J, Chaves J . Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019; 7(1):275. PMC: 6813090. DOI: 10.1186/s40425-019-0746-2. View

12.

Ueda K, Ogasawara N, Ito N, Ohnishi S, Suekane H, Kurose H . Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab. J Clin Med. 2023; 12(6). PMC: 10053370. DOI: 10.3390/jcm12062417. View

13.

Tomiyama N, Tasaki Y, Hamamoto S, Sugiyama Y, Naiki T, Etani T . Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. Int J Urol. 2023; 30(9):754-761. DOI: 10.1111/iju.15198. View

14.

Khan Y, Slattery T, Pickering L . Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers (Basel). 2020; 12(12). PMC: 7764621. DOI: 10.3390/cancers12123750. View

15.

Motzer R, Choueiri T, Mcdermott D, Powles T, Vano Y, Gupta S . Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022; 10(3). PMC: 8935174. DOI: 10.1136/jitc-2021-004316. View

16.

Chen P, Bi F, Tan W, Jian L, Yu X . A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. Front Oncol. 2023; 13:1127448. PMC: 10043594. DOI: 10.3389/fonc.2023.1127448. View

17.

Sepe P, Mennitto A, Corti F, Procopio G . Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. Immunotargets Ther. 2020; 9:273-288. PMC: 7671463. DOI: 10.2147/ITT.S240889. View

18.

Aggen D, Drake C, Rini B . Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clin Cancer Res. 2020; 26(9):2087-2095. DOI: 10.1158/1078-0432.CCR-19-3323. View

19.

Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B . First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021; 4(5):755-765. DOI: 10.1016/j.euo.2021.03.001. View

20.

Sang Y, Yang H, Lee W, Lee S, Kim S, Cheon J . High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers (Basel). 2022; 14(23). PMC: 9738341. DOI: 10.3390/cancers14235985. View